Noxopharm Files Septic Shock Treatment Patent for Veyonda®
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.
Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock.
Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response to repair damaged tissue such as virally-infected lungs. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock. Veyonda is the first drug that blocks STING to be tested in septic shock, including in COVID-19 patients.
Graham Kelly , CEO of Noxopharm, said, “Globally, someone dies every three seconds from septic shock, the same rate as cancer. A cost-effective treatment for septic shock doubles the commercial opportunity for Veyonda.”
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-EAG-LABORATORIES7.5.2021 17:24:11 CEST | Press release
EAG Expands Medical Device Testing Services with New Laboratory
TX-SOFTSERVE7.5.2021 13:02:07 CEST | Press release
SoftServe Wins Learning and Development Honor at 2021 ATD Excellence in Practice Awards
MONUMENT-RE7.5.2021 12:30:22 CEST | Press release
Monument Assurance Belgium and Intégrale Reach Agreement for the Transfer of Intégrale's Entire Portfolio and Staff to MAB
METALS-COMPANY7.5.2021 10:02:11 CEST | Press release
The Metals Company Joins European Industry Alliances to Bolster Battery Supply Chain for the Clean Energy Transition
JOURNÉE-INTERNATIONALE7.5.2021 08:32:04 CEST | Press release
Morocco and UN Celebrate First-Ever International Argan Tree Day
CA-TIGO7.5.2021 02:16:12 CEST | Press release
Tigo Energy Demonstrates Optimization to Installers in Brazil with Stark Renováveis Installation
VIFOR-PHARMA-LTD.6.5.2021 18:02:08 CEST | Press release
93rd Vifor Pharma Group Annual General Meeting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom